A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06946797
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days
  • Carboplatin — DRUG
    Specified dose on specified days
  • Paclitaxel — DRUG
    Specified dose on specified days
  • Pemetrexed — DRUG
    Specified dose on specified days
  • Cisplatin — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)

Key Dates

Start date
Sep 19, 2025
Status verified
May 2026
Primary completion
Feb 5, 2027
Completion
Oct 25, 2028

Study Design

Enrollment
76 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Experimental: Arm B

Primary Outcome Measure

Maximum observed serum concentration (Cmax) of subcutaneous Nivolumab in serum [ Time Frame: Up to 3 weeks ]

Locations (8)

FacilityCityStateZIPSite coordinators
Local Institution - 0032AnchorageAlaska99508-
Local Institution - 0062Los AngelesCalifornia90033-
Local Institution - 0052BoiseIdaho83706-
Local Institution - 0063BoiseIdaho83702-
Local Institution - 0064Post FallsIdaho83854-
Local Institution - 0033ClevelandOhio44109-
Local Institution - 0047ClevelandOhio44106-
Local Institution - 0051AllentownPennsylvania18103-

Find similar trials in Anchorage, AK

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Local Institution - 0032· Anchorage, AKLocal Institution - 0062· Los Angeles, CALocal Institution - 0052· Boise, IDLocal Institution - 0063· Boise, IDLocal Institution - 0064· Post Falls, IDLocal Institution - 0033· Cleveland, OH

Related Studies